Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
EZH2 inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
epithelioid sarcoma follicular lymphoma |
| gptkbp:ATCCode |
L01XX69
|
| gptkbp:brand |
gptkb:Tazverik
|
| gptkbp:CASNumber |
1403254-99-8
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 |
| gptkbp:developedBy |
gptkb:Epizyme,_Inc.
|
| gptkbp:hasInChIKey |
QJQYJZLPKZVEMV-UXBLZVDNSA-N
|
| gptkbp:hasMolecularFormula |
C34H44N4O4
|
| gptkbp:hasSMILES |
CC1=CC(=C(C=C1CN2C=CC(=O)NC2=O)C(=O)N[C@@H]3CCCC[C@H]3N(C)C)N4CCN(CC4)C
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
EPZ-6438
|
| gptkbp:IUPACName |
5-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N-((1S,2R)-2-(dimethylamino)cyclohexyl)-2-methyl-4-(4-methylpiperazin-1-yl)benzamide
|
| gptkbp:mechanismOfAction |
EZH2 methyltransferase inhibitor
|
| gptkbp:molecularWeight |
588.74 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3183531
71276088 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
gptkb:lymphopenia nausea vomiting diarrhea abdominal pain constipation dizziness fatigue headache weight loss cough rash neutropenia thrombocytopenia dyspnea decreased appetite upper respiratory tract infection pyrexia dysgeusia peripheral edema musculoskeletal pain increased creatinine increased ALT increased AST |
| gptkbp:synonym |
gptkb:Tazemetostat
|
| gptkbp:target |
gptkb:EZH2
gptkb:PRC2_complex |
| gptkbp:bfsParent |
gptkb:EZH2
|
| gptkbp:bfsLayer |
7
|